# Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer

> **NCT00403130** · PHASE2 · COMPLETED · sponsor: **George Albert Fisher** · enrollment: 31 (actual)

## Conditions studied

- Breast Cancer
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00403130
- **Lead sponsor:** George Albert Fisher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2010-09
- **Final completion:** 2012-11
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403130, "Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00403130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*